COMPARISON OF MAZAPERINE, RISPERIDONE, AND PLACEBO

本项目旨在评估三种药物的安全性和有效性 剂量的马扎帕汀（20、60和120 mg.出价），与 利培酮（3 mg. bid）和安慰剂，用于治疗 慢性精神分裂症 本研究的具体目的是：（1）确定最佳剂量 慢性精神分裂症受试者与安慰剂相比， 利培酮的最佳剂量;（2）探讨利培酮对 精神分裂症的精神病理学方面，如 作为情绪和焦虑障碍;和（3）评价剂量线性 Mazapertine药代动力学和催乳素对药物的反应， 一组学科。

This project is intended to evaluate the safety and efficacy of three doses of mazapertine (20, 60, and 120 mg. bid), compared with risperidone (3 mg. bid) and placebo, in the treatment of patients with chronic schizophrenia. Specific objectives of this study are to: (1) Determine the optimal dose of mazapertine in chronic schizophrenic subjects, compared to placebo and to the optimal dose of risperidone; (2) Explore the effects on psychopathological aspects of schizophrenia other than psychosis, such as mood and anxiety disturbance; and (3) Evaluate the dose-linearity of mazapertine pharmacokinetics and the prolactin response to the drug in a subgroup of subjects.